Introduction
============

Essential tremor, defined as a 'bilateral, largely symmetric postural or kinetic tremor' ([@aww242-B2]), is a common movement disorder with a reported prevalence of 0.9%, increasing to 4.6% in the population above the age of 65 ([@aww242-B8]). The disease is progressive and significant disabilities occur ([@aww242-B6]; [@aww242-B7]). Hands and arms are predominantly affected but head, voice and leg tremor occur. Twin studies estimated the heritable component of essential tremor between 45% and 90% ([@aww242-B4]). Two small genome-wide association studies (GWAS) (452/436 cases per discovery stage) identified essential tremor associated single nucleotide polymorphisms (SNPs) in *SLC1A2* ([@aww242-B14])*,* coding for the glutamate transporter EAAT2, and in *LINGO1* ([@aww242-B12])*,* involved in oligodendrocyte differentiation and axonal regeneration. Replication studies yielded mixed results for both genes.

Materials and methods
=====================

Patient recruitment
-------------------

Approval was obtained from all responsible ethics committees. All participants gave written consent. Movement disorder specialists at each recruitment site ([Supplementary material](#sup1){ref-type="supplementary-material"}) based the diagnosis mainly on presence of postural and action tremor in the arms exceeding the amplitude seen in enhanced physiological tremor and not attributable to other causes (Parkinson's disease, dystonia, medication). [Supplementary Table 1](#sup1){ref-type="supplementary-material"} lists the sample characteristics of the discovery and replication samples. Controls were ethnically matched to cases and either derived from biobanks PopGen ([@aww242-B3]) and KORA-gen ([@aww242-B17]) (Europe sites) or from North American sites. All patients and controls were of North-Western European (CEU) ancestry. Four hundred and thirty-six samples from Kiel, Tübingen and Innsbruck from the discovery stage of a previous GWAS of essential tremor ([@aww242-B14]) were genotyped anew.

Genotyping
----------

All samples were processed on Axiom® Genome-Wide CEU 1 Array Plate by Affymetrix. Genotypes were called using the Affymetrix Power Tools (APT, version 1.15.1). Genotypes of case and control samples were called together in five batches.

Quality control
---------------

Quality control was performed at sample and marker level using pyGenClean (version 1.2.3) ([@aww242-B5]). Samples were excluded if the missingness rate exceeded 2% or sex information was discordant. We controlled all samples for deviating ethnicity (based on the ethnic classification of 1000 genome samples from CEU, YRI and JPT-CHB populations) and cryptic relatedness \[identity by descent (IBD) \> 0.125\]. Markers failing the following thresholds: missingness rate (\<2%), minor allele frequency rate (\>5%) or Hardy Weinberg Equilibrium (*P* \> 0.0001) were excluded. We examined markers for informative missingness and batch effects ([@aww242-B1]). We report detailed procedures and numbers of excluded samples for individual quality control steps in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}.

Imputation
----------

The pruned dataset was pre-phased using SHAPEIT (version 2.12). We used IMPUTE2 (version 2.3.0) for imputation. In both steps 1000 Genomes Phase I integrated variant set release (v3) in NCBI b37 was used as reference panel. Only imputed variants with a minor allele frequency \> 0.01 and an imputation quality score (INFO) above 0.3 were analysed further.

Tests for association
---------------------

We used (i) a logistic additive model implemented in PLINK (version 1.07) ([@aww242-B10]); and (ii) GEMMA's linear mixed model (version 0.94) ([@aww242-B19]) for association testing. We adjusted for sex and population stratification using 10 dimensions of an IBD-derived multidimensional scaling matrix (PLINK) or using a GEMMA-generated relatedness matrix. The imputed dosage data were analysed using GEMMA.

Replication
-----------

The most promising SNPs (*n =*59) in the finding stage were studied further. We selected SNPs in narrow regional bins in linkage disequilibrium (LD) and controlled their cluster plots. LD bins were defined as SNPs being located in a 500 kb window and with r^2^\> 0.5. We used two Sequenom® panels, processed all samples in one centre and tested for association using logistic models implemented in PLINK. Due to incomplete phenotype data, additional covariates could not be included without severely compromising sample size. We investigated follow-up SNPs in the combined discovery and replication data using logistic regression (PLINK).

Genotyping of variants associated with essential tremor in previous genome-wide association studies
---------------------------------------------------------------------------------------------------

We genotyped all available samples using TaqMan® probes for SNPs rs9652490 in *LINGO1* and rs3794087 in *SLC1A2* and called alleles using QuantStudio^TM^ Real-Time PCR software v1.1 (Life Technologies).

Clinicopathological assessment of patients and tissue handling
--------------------------------------------------------------

Ethics review board approval and participants' written consents were obtained. All patient brain samples are from individuals diagnosed with definite essential tremor ([@aww242-B2]). Control individuals were reported to be free of neurological disorders. Autopsy procedures have been described previously ([@aww242-B11]). One hemisphere of all patient brains was examined histologically in detail by a neuropathologist. Controls underwent a standard neuropathological assessment. Nineteen cases with essential tremor and five control subjects were of Canadian origin, 12 control subjects were of German origin ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}).

DNA/RNA extraction
------------------

We isolated total RNA from 30 mg lateral cerebellar cortex tissue from 19 essential tremor cases and 17 control subjects using AllPrep® DNA/RNA Mini Kit (Qiagen). RNA concentration was measured using NanoDrop® Spectrophotometer and RNA quality determined by gel electrophoresis.

Quantitative reverse transcription polymerase chain reaction
------------------------------------------------------------

We prepared cDNA from 500 ng RNA for quantitative PCR (qPCR) using the RevertAid® H Minus Reverse Transcriptase kit (Thermo Fisher). RNA expression was analysed for the genes *PPARGC1A*, *STK32B*, *CTNNA3*, *ACTB* and the Purkinje cell housekeeping gene *PCP2*. Expression analysis was performed using a StepOnePlus® system and SYBR® Green PCR Master Mix (Thermo Fisher). We performed at least two technical replicates in one qPCR run (four replicates in two qPCR runs for *ACTB*, *PCP2* and *STK32B*). We calculated expression using bioconductor packages ReadqPCR and NormqPCR. Technical replicates were averaged, then gene-expression was normalized using *ACTB* and *PCP2* and expression differences assessed using Student's *t*-test.

Results
=======

Discovery stage
---------------

All discovery samples were genotyped under identical conditions. In the discovery stage 1778 patients with essential tremor and 5376 control samples were genotyped and 416 462 SNPs included after quality pruning. The estimated statistical power was ∼90% for an odds ratio (OR) of 1.3 ([Supplementary Fig. 1](#sup1){ref-type="supplementary-material"}). We first computed marker-wise *P*-values using the logistic additive model implemented in PLINK. QQ-plots showed a high level of genomic inflation (λ = 1.25) despite including 10 dimensions of an IBD-derived multidimensional scaling matrix, indicating incomplete correction for population stratification. Therefore, we also used GEMMA's linear mixed model with adjustment for sex and population stratification, which reduced the genomic inflation to a very low level with λ = 1.01 ([@aww242-B19]). In addition, we analysed the imputed dosage data using GEMMA (Manhattan and QQ-Plots: [Supplementary Figs 2--4](#sup1){ref-type="supplementary-material"}).

Two variants successfully replicated in independent cohort
----------------------------------------------------------

In the replication stage we genotyped an independent cohort of 1029 patients with essential tremor and 1065 control samples for 59 best markers selected from all three analyses (PLINK, GEMMA, GEMMA imputed data). We applied logistic regression analysis (PLINK) in the replication stage and in a combined analysis of both stages. Two variants, both selected from the GEMMA first stage analysis, met a Bonferroni-corrected significance threshold of *P* = 8.47 × 10^−4^ ([Tables 1](#aww242-T1){ref-type="table"} and [2](#aww242-T2){ref-type="table"}). The first variant rs10937625 \[*P* = 7.36 × 10^−4^, OR = 0.77, 95% confidence interval (CI) 0.66--0.90\] locates to an intronic region of *STK32B* ([Fig. 1](#aww242-F1){ref-type="fig"}A), coding for a serine/threonine kinase. The second variant rs17590046 \[*P* = 6.81 × 10^−4^, OR = 0.75 (95% CI 0.64--0.89)\] lies in an intron of *PPARGC1A* ([Fig. 1](#aww242-F1){ref-type="fig"}B), a transcriptional coactivator. LD analysis showed no additional associated markers in neighbouring genes ([Fig. 1](#aww242-F1){ref-type="fig"}A and B). None of the SNPs chosen based on the PLINK analysis of the discovery stage or the imputed data was successfully replicated. Therefore, we do not report any imputed data. Combined analysis of first and second stage data revealed a region on chromosome 10q21.3 containing variants with small *P*-values in PLINK as well as GEMMA analysis, including three intronic variants in the adhesion molecule gene *CTNNA3***\[**rs7903491, *P* = 2.49 × 10^−7^, OR = 1.10 (95% CI 1.03--1.18); rs12764057, *P* = 1.19 × 10^−8^, OR = 1.17 (95% CI 1.09--1.26) and rs10822974, 1.65 × 10^−7^, OR = 1.16 (95% CI 1.08--1.24)\] ([Fig. 1](#aww242-F1){ref-type="fig"}C). The variants are located close to each other but are not in strong LD (r^2^\< 0.8) and testing for independent haplotypic effects using PLINK showed no correlation ([Fig. 1](#aww242-F1){ref-type="fig"}C). Association results for individual stages and combined analysis of the 20 most significant markers are summarized in [Supplementary Table 4](#sup1){ref-type="supplementary-material"}. The minor allele frequencies of successfully replicated markers rs10937652 and rs1750046 were highly consistent between different recruiting centres and discovery/replication samples while higher deviations between stages were observed for markers in *CTNNA3* ([Supplementary Table 5](#sup1){ref-type="supplementary-material"} and [Supplementary Fig. 5](#sup1){ref-type="supplementary-material"}). Heterogeneity metrics of associated markers between different stages and recruitment sites are displayed in [Table 1](#aww242-T1){ref-type="table"} and forest plots in [Supplementary Figs 6--10](#sup1){ref-type="supplementary-material"}. In many studies, including this one, the age at onset data follow a bimodal distribution ([Supplementary Fig. 11](#sup1){ref-type="supplementary-material"}). Stratification into early (\<25 years) and late (\>50 years) age at onset groups did not reveal large differences in the allele frequencies of the top 20 markers between both groups ([Supplementary Table 6](#sup1){ref-type="supplementary-material"} and [Supplementary Fig. 12](#sup1){ref-type="supplementary-material"}). We do not present subgroup analyses because these did not provide additional insights. Figure 1**Fine mapping of 500 kb windows centred around each of the three essential tremor-associated loci.***Top to bottom*: Chromosome ideogram followed by genes (horizontal line) and their coding regions (vertical bars), negative logarithmic *P*-values of all markers for the discovery stage (left *y*-axis) against chromosomal position (*x*-axis) and recombination rates for the genomic positions (right *y*-axis) in pink. *Bottom*: Heatmap indicating LD. Saturated red indicating high LD, white indicating no LD. (**A**) *STK32B*; (**B**) *PPARGC1A*; and (**C**) *CTNNA3*.Table 1Association results for the three associated lociDiscovery stageReplication stageCombined stagesHeterogeneitySNPCHRBPMinor allele (a)Major allele (A)*P*OR (95% CI)*P*OR (95% CI)*P*OR (95% CI)I^2^Tau^2^rs1093762545 128 159CT4.42 × 10^−6^0.80 (0.73--0.88)7.36 × 10^−4^0.77 (0.66--0.90)5.21 × 10^−10^0.80 (0.74--0.87)39.6%0.0049rs17590046424 362 541CT3.39 × 10^−6^0.80 (0.73--0.88)6.81 × 10^−4^0.75 (0.64--0.89)1.39 × 10^−9^0.79 (0.72--0.86)47.6%0.0082rs127640571068 845 715GT3.99 × 10^−5^1.28 (1.19--1.39)0.2751.07 (0.94--1.22)1.19 × 10^−8^1.17 (1.09--1.26)61.6%0.0089rs108229741068 850 419GA3.02 × 10^−5^1.27 (1.18--1.37)0.7960.98 (0.86--1.13)1.65 × 10^−7^1.16 (1.08--1.24)67.3%0.0118rs79034911068 917 164AG1.10 × 10^−6^1.20 (1.11--1.30)0.4071.05 (0.93--1.20)2.49 × 10^−7^1.10 (1.03--1.18)92.4%0.0676[^2]Table 2Genotype counts and minor allele frequencies for the three associated lociGenotype counts casesGenotype counts controlsSNPCHRBPMinor Allele (a)Major Allele (A)aaaAAAMAFaaaAAAMAFrs1093762545 128 159CT11394216220.2182403249234100.2615rs17590046424 362 541CT6877518880.1668263211240470.2054rs127640571068 845 715GT48512839300.4175898297425370.3721rs108229741068 850 419GA62512716370.49761827311613120.5412rs79034911068 917 164AG45313118810.41911347320818480.4609[^3]

No replication of previously reported associations
--------------------------------------------------

We genotyped SNPs rs3794087 in the *SLC1A2* gene and rs9652490 in *LINGO1*, which were associated with essential tremor in previous GWAS in all available samples (2847 cases/1977 controls) ([Supplementary material](#sup1){ref-type="supplementary-material"}). Controls provided by Kora and PopGen could not be included because we could not obtain DNA for these samples. Neither of the two SNPs nor neighbouring SNPs showed a significant association with essential tremor ([Supplementary Table 7](#sup1){ref-type="supplementary-material"}, [Supplementary Figs 13](#sup1){ref-type="supplementary-material"} and [14](#sup1){ref-type="supplementary-material"}).

The *STK32B* SNP rs10937625 is located in a regulatory region
-------------------------------------------------------------

Variant annotation using HaploReg3 revealed that rs10937625 is located in a DNase hypersensitive region but did not provide further information for the other essential tremor-associated SNPs. A BioGRID search did not find any evidence for interactions or shared GO Processes between the genes *STK32B*, *PPARGC1A* and *CTNNA3*.

Increased expression of *STK32B* in brains of patients with essential tremor
----------------------------------------------------------------------------

We examined the expression of *STK32B*, *PPARGC1A* and *CTNNA3* in lateral cerebellar cortex of 19 patients with essential tremor and 17 control subjects by reverse transcription (RT)-qPCR. Age at death, post-mortem intervals, and sex did not significantly differ between patients and controls. The expression of *STK32B* was significantly increased in essential tremor brains compared to control brains (*P* = 0.026) ([Supplementary Table 8](#sup1){ref-type="supplementary-material"} and [Supplementary Fig. 15](#sup1){ref-type="supplementary-material"}). The expression difference was not associated with genotype at rs10937625 ([Supplementary Table 9](#sup1){ref-type="supplementary-material"} and [Supplementary Fig. 16](#sup1){ref-type="supplementary-material"}). A linear regression model identified disease status as the only determinant of *STK32B* expression ([Supplementary Fig. 15](#sup1){ref-type="supplementary-material"}). We found no genotype or phenotype related differences in the expression of *PPARGC1A* or *CTNNA3*.

*STK32B* marker rs10937625 associated with eQTL in public database
------------------------------------------------------------------

In the Braineac eQTL database, the expression of probeset 2716778 (Affymetrix Probeset ID, chr4:5532972-5533090) located in the *STK32B* coding region is highly associated with the genotype of SNP rs1093762 (*P* \< 0.0008) in cerebellar cortex but not in other brain regions ([@aww242-B15]) ([Supplementary Fig. 18](#sup1){ref-type="supplementary-material"}). We observed an additive, negative effect of the minor, protective allele on expression of the *STK32B* probe set. Expression of *PPARGC1A* and *CTNNA3* were not associated with the genotypes of the corresponding essential tremor-associated SNPs in the Braineac data.

Discussion
==========

Standard analysis of our discovery stage data using PLINK suggested a high level of population stratification. GEMMA's relatedness matrix is known to be particularly suited for the correction of population stratification. The very low mean χ^2^ metric of 1.0048 in the GEMMA analysis made us suspect significant levels of overcorrection and loss of power. To minimize type 1 errors (PLINK) as well as type 2 errors (GEMMA) we selected the top SNPs from all analysis types for replication. Only the third and fourth ranked SNPs in the GEMMA analysis of the discovery stage (rs10937625, rs17590046) were significantly associated with essential tremor in the replication stage. We choose to report three additional SNPs in the *CTNNA3* gene, which were among the top variants in the discovery sample in both the PLINK as well as the GEMMA analysis. However, it has to be noted that these SNPs failed replication and carry an increased risk of a type 1 error.

The biological function of the serine/threonine kinase *STK32B* is unknown. The gene is located in a 520 kb deletion causing the rare skeletal dysplasia Ellis-Van-Creveld syndrome ([@aww242-B13]). The association of rs10937625 in the *STK32B* gene with essential tremor, the increased expression in the cerebellar cortex of patients with essential tremor and the association of the protective minor allele with reduced *STK32B* expression in cerebellar cortex in the Braineac eQTL database support a role of *STK32B* in the pathogenesis of essential tremor. We found no association between the rs10937625 genotype and *STK32B* expression in our samples which might be a related to the small sample size.

The other essential tremor-associated SNP, rs17590046 is located in the *PPARGC1A* gene encoding the peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α). PGC-1α is a transcriptional coactivator of genes involved in energy metabolism and mitochondrial function ([@aww242-B18]). Genetic and functional studies suggest a role in the pathogenesis of various neurodegenerative disorders ([@aww242-B16]). We found no evidence that rs17590045 is related to the expression of *PPARGC1A*. The *CTNNA3* gene, harbouring the SNPs rs7903491, rs12764057, rs10822974 codes for catenin alpha 3, a cell--cell adhesion molecule genetically linked to Alzheimer's disease ([@aww242-B9]).

We are fully aware that the most severe limitations of our study are the lack of genome-wide significance of the replicated markers in the discovery stage and incomplete harmonization of clinical data throughout our cases. The lack of genome-wide significance in the GEMMA analysis of the first stage might be due to overcorrection in the GEMMA based analysis. Therefore, we would like to strongly encourage replication to confirm or refute the hypotheses provided by our study. Nevertheless, we would also like to emphasize that this is by far the largest GWAS in essential tremor and we are confident that it will be the driving force for the next generation of genetics and molecular studies to come.
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Click here for additional data file.
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Web resources
=============

The URLs for data presented herein are as follows:

HaploReg V3: <https://www.broadinstitute.org/mammals/haploreg/haploreg_v3.php>

BioGRID: <http://thebiogrid.org/>

BRAINEAC: <http://www.braineac.org/>

Supplementary material
======================

[Supplementary material](#sup1){ref-type="supplementary-material"} is available at *Brain* online.

GWAS

:   genome-wide association study

LD

:   linkage disequilibrium

RT-qPCR

:   reverse transcription-quantitative polymerase chain reaction

SNP

:   single nucleotide polymorphism

[^1]: \*These authors contributed equally to this work.

[^2]: SNP = dbSNP ID of the marker; CHR = chromosome; BP = chromosomal position (GRCh37), OR (95% CI) = odds ratio with 95% confidence interval; I^2^= ratio of true heterogeneity to total observed variation; tau^2^= between studies variance. Heterogeneity metrics were calculated between samples included in: discovery stage with European descent, discovery stage with North American descent, replication stage with European descent and replication stage with North American descent.

[^3]: MAF = minor allele frequency; SNP = dbSNP ID of the marker; CHR = chromosome; BP = chromosomal position (GRCh37).
